華盛昌(002980.SZ)：公司是紅外人體測温領域的標杆企業，產品累計銷售超數百萬台
格隆匯2月9日丨華盛昌(002980.SZ)於2023年2月7日、2月8日接受機構調研時表示，公司是紅外人體測温領域的標杆企業，產品累計銷售超數百萬台，廣泛用於各級醫院、企事業單位、家庭和個人等場合，強大的研發實力，多年市場經營，公司積累大量的醫療客户資源和醫療器械產品研發、生產經驗。在醫療領域，公司看好家用醫療和體外診斷領域。
(1)家用醫療：家用醫療器械在歐美日發達國家己進入穩定成熟期，我國起步雖晚，但人口眾多，醫療衞生系統改善空間大，已是全球第二大醫療市場。近年來在亞健康羣體增加、慢病患者激增、老齡化加重等因素驅動下，家用檢測、康復治療類醫療器械需求逐步上升。公司以“將測量科技創新應用於醫療健康，使專業技術平價化，讓更多的人享受科技帶來的美好生活”為出發點，根據市場需求，研發相關產品。
(2)體外診斷：隨着人口老齡化、保險覆蓋率及支出不斷增加、收入增長等因素的驅動，加之體外診斷能夠便捷、低成本、低傷害的為醫護人員和個人提供精確、早期的臨牀診斷信息，為疾病發現、治療、監測提供有效依據，並能大大節省醫療費用，已成為醫療決策的重要依據。目前，體外診斷產業已成為當今世界上最活躍、發展最快的行業之一。公司自上市以來積極向醫療大健康領域拓展，憑藉以往積累的經驗和技術，在人體紅外測温技術平台的基礎上，深入IVD體外診斷醫療領域，建立了分子診斷技術平台、免疫層析技術平台，投資建立了新冠抗原檢測試劑研發實驗室和萬級潔淨生產車間，具有ISO13485醫療器械-質量管理體系認證、醫療器械生產許可和醫療器械經營許可資質。公司在疫情蔓延初期，投入建設免疫層析技術平台，加大新冠免疫層析膠體金抗原檢測產品研發投入，組建新冠抗原試劑研發團隊。公司新冠病毒抗原快速檢測試劑盒已取得歐盟專業類CE認證、自測類CE認證和俄羅斯註冊，在積極申報國內註冊。公司自研的實時熒光定量PCR分析儀已取得歐盟CE認證、英國MHRA註冊和美國FDA註冊，在積極申報國內註冊。公司建立了生物醫療實驗室，加強生物、醫學專業團隊建設，努力抓住醫療行業不斷呈現的新發展機遇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
